The purpose of this study is to collect information about treatment recommendations based on ctDNA testing and whether treatment changes based on ctDNA information result in better outcomes for patients with pancreatic cancer.
Study Type
OBSERVATIONAL
Information collection about how SIGNATERA™ ctDNA testing changes how doctors make treatment recommendations to patients with early-stage pancreatic cancer.
Inova Schar Cancer Institute
Fairfax, Virginia, United States
Impact of SIGNATERA™ on treatment decisions
Examine the impact of SIGNATERA™ on treatment decisions as determined by physician questionnaires
Time frame: 2 years
Frequency of positive SIGNATERA™ ctDNA testing
Determine the frequency of positive SIGNATERA™ ctDNA testing in patients with R/BR PDAC at baseline and after surgical resection
Time frame: 2 years
Overall survival of patients managed with SIGNATERA™ ctDNA data
Compare overall survival of patients managed with available SIGNATERA™ ctDNA data to historical controls
Time frame: 2 years
Progression-free survival of patients managed with SIGNATERA™ ctDNA data
Compare progression-free survival of patients managed with available SIGNATERA™ ctDNA data to historical controls
Time frame: 2 years
Patient satisfaction of SIGNATERA™ ctDNA on treatment recommendations
Assess patient satisfaction regarding the potential role of SIGNATERA™ ctDNA on treatment recommendations using validated questionnaires
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.